CA2218679A1 - Apopa?ne - Google Patents

Apopa?ne Download PDF

Info

Publication number
CA2218679A1
CA2218679A1 CA002218679A CA2218679A CA2218679A1 CA 2218679 A1 CA2218679 A1 CA 2218679A1 CA 002218679 A CA002218679 A CA 002218679A CA 2218679 A CA2218679 A CA 2218679A CA 2218679 A1 CA2218679 A1 CA 2218679A1
Authority
CA
Canada
Prior art keywords
apopain
activity
parp
cell
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002218679A
Other languages
English (en)
Inventor
Douglas K. Miller
Nancy A. Thornbery
Ambereen Ali
Donald W. Nicholson
John P. Vaillancourt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2218679A1 publication Critical patent/CA2218679A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un enzyme isolé et purifié appelé apopaïne, des procédés relatifs à l'utilisation de l'apopaïne pour cribler les composés qui modulent l'activité de l'apopaïne, et des composés identifiés par criblage. Une molécule d'ADN synthétique qui code l'apopaïne pleine longueur est obtenue à partir de l'enzyme purifié. On formule l'ADN synthétique qui code l'apopaïne de manière à optimiser l'expression dans différentes cellules de recombinaison. Les clones d'ADN produisent par recombinaison l'apopaïne pleine longueur et ses dérivés. L'apopaïne native purifiée et l'apopaïne de recombinaison sont utiles pour identifier les modulateurs d'activité de l'apopaïne et, partant, les modificateurs des conditions pathologiques liées aux effets pro-inflammatoires ou proapoptotiques de l'apopaïne. Les molécules d'apopaïne anti-sens sont utiles dans les traitements qui permettent de réduire ou d'éliminer les effets pro-inflammatoires ou proapoptotiques de l'apopaïne, tandis que la transplantation génétique ou la thérapie génétique reposant sur l'apopaïne sont utiles pour accroître les mêmes effets. Ces moyens thérapeutiques sont bénéfiques dans le traitement des maladies immunes, prolifératives et dégénératives, y compris, entre autre, les syndromes immunodéficitaires acquis (tels que le SIDA), les maladies auto-immunes, les infections pathogènes, les liaisons cardiovasculaires et neurologiques, l'alopécie, le viellissement, le cancer, la maladie de Parkinson et la maladie d'Alzheimer.
CA002218679A 1995-04-21 1996-04-17 Apopa?ne Abandoned CA2218679A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42655795A 1995-04-21 1995-04-21
US08/426,557 1995-04-21

Publications (1)

Publication Number Publication Date
CA2218679A1 true CA2218679A1 (fr) 1996-10-24

Family

ID=23691273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002218679A Abandoned CA2218679A1 (fr) 1995-04-21 1996-04-17 Apopa?ne

Country Status (4)

Country Link
EP (1) EP0822983A4 (fr)
JP (1) JPH11504209A (fr)
CA (1) CA2218679A1 (fr)
WO (1) WO1996033268A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538121B1 (en) * 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US6835555B1 (en) 1994-11-01 2004-12-28 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
JP2000505457A (ja) * 1996-02-23 2000-05-09 メルク エンド カンパニー インコーポレーテッド アポペインの結晶構造及びその使用
US6180402B1 (en) * 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
GB2324529A (en) * 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
DE19820328A1 (de) * 1998-05-07 1999-11-11 Roche Diagnostics Gmbh Verfahren und Reagenz zum Nachweis apoptotischer Zellen bzw. einer bei Apoptose aktivierten Protease
JP2002515490A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
DE10006889A1 (de) * 2000-02-16 2001-09-06 Procorde Gmbh Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen
AU2001295778A1 (en) * 2000-10-20 2002-04-29 Inpharmatica Limited Novel cysteine proteases and uses thereof
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538121B1 (en) * 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US7097972B1 (en) * 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis

Also Published As

Publication number Publication date
JPH11504209A (ja) 1999-04-20
EP0822983A1 (fr) 1998-02-11
EP0822983A4 (fr) 2004-12-15
WO1996033268A1 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
US5798442A (en) Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
Nicholson et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
CA2218679A1 (fr) Apopa?ne
Hooper et al. Membrane protein secretases
AU661270B2 (en) Chymotrypsin-like proteases and their inhibitors
US5424205A (en) Amyloidin protease and uses thereof
Tagliarino et al. μ-calpain activation in β-lapachone-mediated apoptosis
US7115260B2 (en) Interleukin-1β converting enzyme like apoptotic protease-6
US6686459B1 (en) Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use
EP0759079B1 (fr) ADN CODANT UN PRECURSEUR DE LA CYSTEINE PROTEINASE III APPARENTEE A L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1-BETA (ICE rel-III)
AU1459200A (en) Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
JP3750136B2 (ja) インターロイキン−１β変換酵素関連システインプロテイナーゼ▲ＩＩ▼（ＩＣＥ▲下ｒｅｌ▼−▲ＩＩ▼）の前駆体をコードするＤＮＡ
US6274318B1 (en) Apoptotic protease Mch6, nucleic acids encoding same and methods of us
US7247438B1 (en) Methods of identifying agents which enhance caspase activity
Chen et al. Expression and Purification of Human Interleukin-1β Converting Enzyme fromTrichoplusia niInsect Cells Using a Baculovirus Expression System
US6890721B1 (en) Interleukin-1β converting enzyme like apoptotic protease-6
WO1998036057A9 (fr) Activite d'une thymocyte caspase et selection negative
Hong et al. Caspase-3-like Death Protease is Inhibited by Interleukin-7
EP0885243A1 (fr) Structure cristalline d'apopaine et son utilisation
DOUGLAS et al. The IL-lP Converting Enzyme as a Therapeutic Target
Reboud-Ravaux Proteasome inhibitors
AU2922402A (en) Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
AU2922002A (en) Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead